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Background: Hotspot mutations in the promoter of the gene coding for telomerase
reverse transcriptase (TERT) have been described and proposed to activate gene expres-
sion.
Objectives: To investigate TERTmutation frequency, spectrum, association with expres-
sion and clinical outcome, and potential for detection of recurrences in urine in patients
with urothelial bladder cancer (UBC).
Design, setting, and participants: A set of 111 UBCs of different stageswas used to assess
TERT promoter mutations by Sanger sequencing and TERT messenger RNA (mRNA)
expression by reverse transcription-quantitative polymerase chain reaction. The two
most frequent mutations were investigated, using a SNaPshot assay, in an independent
set of 184 non–muscle-invasive and 173 muscle-invasive UBC (median follow-up:
53 mo and 21 mo, respectively). Voided urine from patients with suspicion of incident
UBC (n = 174), or under surveillance after diagnosis of non–muscle-invasive UBC
(n = 194), was tested using a SNaPshot assay.
Outcome measurements and statistical analysis: Association of mutation status with
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Results and limitations: In the two series, 78 of 111 (70%) and 283 of 357 (79%) tumors
harbored TERT mutations, C228T being the most frequent substitution (83% for both
series). TERT mutations were not associated with clinical or pathologic parameters, but
were more frequent among FGFR3 mutant tumors ( p = 0.0002). There was no associa-
tion between TERT mutations and mRNA expression ( p = 0.3). Mutations were not
associated with clinical outcome. In urine, TERT mutations had 90% specificity in
subjects with hematuria but no bladder tumor, and 73% in recurrence-free UBC patients.
The sensitivity was 62% in incident and 42% in recurrent UBC. A limitation of the study is
its retrospective nature.
Conclusions: Somatic TERT promoter mutations are an early, highly prevalent genetic
event in UBC and are not associated with TERT mRNA levels or disease outcomes. A
SNaPshot assay in urine may help to detect UBC recurrences.
# 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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Urothelial bladder cancer (UBC) is heterogeneous at the
clinical, pathologic, and genetic levels. Approximately 75%
of newly diagnosed tumors are non–muscle invasive (Ta,
Tis, and T1); most of them recur and 15–20% progress to
invade muscle. The remaining 25% of patients present with
muscle-invasive tumors and have a 5-yr survival of <50%
[1–3]. Fibroblast growth factor receptor 3 (FGFR3) is the
most commonly mutated gene in UBC, with an overall
frequency of 60% [4–6]. Mutations in Harvey rat sarcoma
viral oncogene homolog (HRAS), neuroblastoma RAS viral
(v-ras) oncogene homolog (NRAS), Kirsten rat sarcoma viral
oncogene homolog (KRAS), and phosphatidylinositol-4,5-
bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) are
less frequent [6,7]. FGFR3 mutations are associated with
stage and grade and are very common in pTa and grade 1/2
tumors. Thismakes FGFR3mutation analysis in voided urine
a useful tool for diagnosing recurrent disease after a primary
non–muscle-invasive bladder cancer (NMIBC) [8,9].
Telomerase increases telomere length at chromosome
ends. This activity is crucial for proliferating cells: Without
telomerase, chromosomes are shortened every cell-division
cycle, leading to replicative senescence and genomic
instability [10,11]. Telomerase is active in stem cells but
becomes downregulated in differentiated cells in somatic
tissues. By contrast, it becomes reactivated inmany tumors.
Somatic hotspot mutations in the promoter of the gene
coding for telomerase reverse transcriptase (TERT) catalytic
subunit have recently been described in 71% of sporadic
melanomas; germline mutations have also been reported in
a melanoma kindred [12,13]. The somatic mutations were
mutually exclusive C-to-T transitions at nucleotides
1,295,228 (C228T) and 1,295,250 (C250T). These are the
first hotspot somaticmutations reported in a gene promoter
in human cancers and have been proposed to enhance
TERT expression through the creation of novel binding sites
for E-twenty-six (ETS)/ELK transcription factors [12,13].
Nevertheless, direct proof for this mechanism is absent.
Interestingly, Huang et al. reported the C228T mutation in
three of three UBC cell lines [12] and, in a survey of different
tumor types, TERT promoter mutations were also found
in UBC, hepatocarcinoma, glioblastoma, oligodendroglioma,
and myxoid liposarcomas, but not in breast, colorectal, and
prostate cancers [14]. However, the number of bladdertumors analyzed was small and clinical or pathologic
information was not available [14].
In this paper, we investigate the frequency of TERT
promoter mutations in two large series of UBC. In the first
one, lacking outcome information, we assessed the rela-
tionship between TERTmutations and TERTmessenger RNA
(mRNA) expression; in the second, with patient follow-up,
we assessed the relationship between mutations and
outcome. Finally, we explored whether mutation detection
in urine may be used to identify tumor recurrence.
2. Materials and methods
2.1. Patient characteristics
A set of 111 patientswith associated frozen tumor samples came from the
Spanish Bladder Cancer/EPICURO Study [15,16] and from the Integrated
Study of Bladder Cancer (ISBLAC). Clinical and sociodemographic
information was retrieved from hospital records through a structured
questionnaire. Subjects were defined as former smokers if they quit
smoking 1 yr before the date of interview. A second set of 357 patients,
with associated formalin-fixed paraffin embedded (FFPE) tumor samples
and follow-up information, came from the Erasmus Medical Center and
other hospitals in the Netherlands. This cohort comprises 184 patients
with primaryNMIBC selected to contain a 50:50 distribution of caseswith
or without progression; the latter was defined by the development of
MIBC. It also comprises173patientswhohaveundergonea cystectomy for
primaryMIBC, stage pT2-4. Cause of death for patients in theMIBC cohort
was determined from hospital records and/or direct contact with general
practitioners. Staging and grading were performed according to the TNM
2002 classification and the three-grade 1973 World Health Organization
classification. To confirm staging/grading and ensure uniformity of
classification criteria, expert pathologists reviewed diagnostic slides from
all tumor blocks. Table 1 shows the characteristics of patients whose
tumor samples were studied.
For the urine study, samples were obtained from a consecutive,
prospectively sampled collection of urine specimens from two centers
(Hospital del Mar, Barcelona, Spain; and Erasmus MC, Rotterdam,
Netherlands) participating in the European Community Seventh Frame-
work program–funded ‘‘Prediction of bladder cancer disease course using
risk scores that combine molecular and clinical risk factors’’ (UROMOL)
study (EU-7FP UROMOL #201663). Samples were obtained prior to
cystoscopy at the time when a primary UBC was diagnosed (n = 135), or
frompatients lackingapriorhistoryofUBCwhopresentedwithhematuria
for diagnostic work-up and lacked visible bladder tumors at cystoscopy
(n = 39). Additional samples (n = 395) were obtained during surveillance
for relapsed disease (recurrence or progression) in 194 patients with
NMIBC. Primary tumor or recurrence was defined by the presence of a











Age, yr, median 76 70 71
Sex Female 13 (12) 46 (25) 28 (16)
Male 98 (88) 138 (75) 145 (84)
Stage pTa + pTis 63 (57) 107 (58) –
pT1 28 (25) 77 (42) –
pT2 13 (12) – 72 (42)
pT3 3 (3) – 75 (43)
pT4 3 (3) – 26 (15)
Grade G1 27 (24) 14 (8) 1 (1)
G2 28 (25) 101 (55) 13 (7.5)
G3 56 (51) 69 (37) 159 (92)
Follow-up, mo, median – 53 21
End point Progression to MIBC – 90 (49) –
Local or distant progression to MIBC – – 78 (45)
Died of disease – – 65 (37)
Died of other causes – – 36 (21)
Alive at follow-up – – 37 (21)
Lost to follow-up – – 35 (20)
TERT status Mut 78 (70) 147 (80) 136 (79)
WT 33 (30) 37 (20) 37 (21)
TERT mutations* C228T 65 (83) 121 (82) 113 (83)
C228A 1 (1.5) 3 (2) 3 (2)
CC242/243TT 2 (2.5) NA NA
C250T 10 (13) 23 (16) 20 (15)
Mut = mutant; NMIBC = non–muscle-invasive bladder cancer; TERT = telomerase reverse transcriptase; WT = wild type.
* The C242T mutation was not assessable with the SNaPshot assay.
Table 2 – Characteristics of tumors and patients used for urine
diagnostic assays






Patients, no. 45 90
Stage pTa 39 (87) 53 (59)
pTis 3 (3)
pT1 5 (11) 21 (23)
pT2-4 1 (2) 13 (15)
Grade G1 17 (38) 27 (30)
G2 26 (58) 17 (19)
G3 2 (4) 46 (51)
Patients under surveillance
after NMIBC diagnosis*
Patients, no. 118 76
With relapsing tumors
Stage pTa 78 (90) 40 (71)
pTis 2 (4)
pT1 2 (2) 7 (12)
pT2-4 5 (6) 4 (6)
pTx 2 (2) 3 (7)
Grade G1 25 (29) 23 (35)
G2 52 (60) 13 (23)
G3 8 (9) 19 (32)





NMIBC = non–muscle-invasive bladder cancer.
* Relapsing tumors include both recurrences and progression detected in
patients with initial diagnosis of NMIBC.
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included in the urine study.
All patients provided written informed consent. The ethics commit-
tees of the participating institutions approved all studies. Samples from
the Netherlands were obtained according to the Federation of Dutch
Medical Scientific Societies’ Code for Proper Secondary Use of Human
Tissues in the Netherlands (http://www.federa.org/).
2.2. Cell lines
UBC cell lines (Supplemental Table 1) were cultured under standard
conditions and used for DNA extraction when at 70–80% confluence. All
cultures were Mycoplasma free; their identity was tested by analysis of
known genetic mutations.
2.3. DNA isolation and mutation analyses
Tumor cell-containing regionsweremacrodissected from frozen blocks or
FFPE sections after examination of hematoxylin and eosin–stained
sections. For MIBC cases, DNA was isolated from tumor obtained at the
time of cystectomy or, in case of pT0, of incident transurethral resection.
Tumor DNA and leukocyte DNA were extracted using the Qiagen kit for
blood and tissue, according tomanufacturer’s instructions (QiagenGmbH,
Hilden, Germany). Sanger sequencing of polymerase chain reaction (PCR)
products was used to identify all possible mutations in the first set of
patients (Fig. 1A). A 163-base pair (bp) PCR product encompassing the
proximal TERT promoter was amplified (primers: CAGCGCTGCCT-
GAAACTC [forward] and GTCCTGCCCCTTCACCTT [reverse]); for some
samples, a broader 488-bp regionof the promoterwas amplified (primers:
AGCACCTCGCGGTAGTGG [forward], GGCCGATTCGACCTCTCT [reverse]).
[(Fig._1)TD$FIG]
Fig. 1 – Somatic telomerase reverse transcriptase (TERT) promotermutations in urothelial bladder cancer (UBC). (A) TheC228T and C242T/C243Tmutations are
detected in tumor DNA but not in leukocyte DNA (Sanger sequencing). (B) Mutation assay for the indicated nucleotides in the promoter of the TERT gene.
Upper panel: Control sample with wild-type peaks for positions C228T and C250T (from left to right). The lower panels showmutant samples and the nature
of the mutation has been indicated. Note that the assay detects the mutations from the complementary strand, hence the mutations are indicated as G228A,
G228T, and G250A. (C) Distribution of TERT promoter mutations in UBC according to T and G. Tumors are categorized in three groups: low-risk non–muscle-
invasive bladder cancer (NMIBC) (TaG1/G2) (Low R), high-risk NMIBC (TaG3, T1G2/G3) (High R), and MIBC (>T2) for Spain (Sanger sequencing) and the
Netherlands (SNaPshot; Applied Biosystems, Foster City, CA, USA). Absolute numbers of cases are given for eachmutation and group. (D) TERTmessenger RNA
levels in bladder tumors assessed by reverse transcriptase-quantitative polymerase chain reaction (n = 60); results show the comparison of wild type versus
mutant tumors and the comparison of the three tumor groups according to T and G. *** p = 0.001. WT = wild type; MT =mutant type.
E U RO P E AN URO LOG Y 6 5 ( 2 0 1 4 ) 3 6 0 – 3 6 6 363PCR conditions can be provided on request to the authors. FGFR3mutation
assays were performed as described [8].
For the TERT mutational analysis in the second patient group, we
designed a SNaPshot assay (Invitrogen Corp, Carlsbad, CA, USA) through
a PCR (155 bp) covering the two most frequent mutations identified
(primers: AGCGCTGCCTGAAACTCG [forward], CCCTTCACCTTCCAGCTC
[reverse]), similar to the previously designed FGFR3 mutation assay [8].
The PCR was followed by a single-nucleotide extension using probes
annealing to the amplicon adjacent to the mutation site. Probe sequences
were: T23GGCTGGGAGGGCCCGGA for mutation 1,295,228 (C228T/A) and
T39CTGGGCCGGGGACCCGG for 1,295,250 (C250T) at 1 mM and 1.5 mM,
respectively (ABI PRISM SNaPshot Multiplex Kit; Applied Biosystems,
FosterCity,CA,USA). Theproductswereanalyzed(ABIPRISM3100Genetic
Analyzer; Applied Biosystems, Foster City, CA, USA) with the label
indicating the presence or absence of a mutation. Genescan Analysis
Software v.3.7 (AppliedBiosystems, Foster City, CA,USA)wasused for data
analysis (Fig. 1B).For urine DNA extraction and mutation analysis, cell pellets were
washed twice with phosphate-buffered saline, after thawing, by
centrifugation for 5 min at 6000 rpm (3000 g). DNA was extracted using
the QiAamp Mini and Blood mini kit (Qiagen NV, Venlo, Netherlands)
according to the manufacturer’s protocol. TERT mutational analysis was
performed using the SNaPshot assay.
Reverse transcriptase-quantitative PCR (RT-qPCR) was used to assess
TERT RNA expression (see Supplement).
2.4. Statistical and bioinformatics analyses
The Predictive Analytics Software v.19 (IBM Corp., Armonk, NY, USA) was
used. Statistical differences were considered significant if p < 0.05. The
chi-square andFisher exact testswere used todetermine the relationships
between different variables. Statistical differences between groups were
assessed using a nonparametric Wilcoxon test, as appropriate. The log-
rank test was used for survival analysis. In the NMIBC group, all outcomes
E U RO P E AN URO LOGY 6 5 ( 2 0 1 4 ) 3 6 0 – 3 6 6364other than progression appear as censored in the Kaplan-Meier curve.
Bioinformatics analysis of the TERT promoter sequence is detailed in the
Supplement.
3. Results
3.1. TERT promoter mutations in bladder cancer
We first analyzed the occurrence of mutations in UBC cell
lines and tumors using Sanger sequencing of PCR products.
Of 32 lines analyzed, 4werewild type and 28 (87%) harbored
the C228T (n=25) or C250T (n=3) mutations (Supplemental
Table 1). The somatic nature of thesemutations could not be
evaluated due to lack of germline DNA.
Among the 111 UBCs from Spain, covering the full
spectrum of the localized disease, 78 were mutated (70%)
(Table 1). The most common mutation was C228T (n = 65),
followed by C250T (n = 10); two additional rare mutations
were C242T/C243T (n = 2) and C228A (n = 1). All mutations
were mutually exclusive; their somatic nature was con-
firmed in 10 cases (Fig. 1A). The C250T mutation was
significantly less common in UBC than in melanoma
(p = 0.00003); the C228T/C229T mutation reported in
melanoma was not found in UBC. TERT mutations were
not associated with age, sex, or smoking. The frequency of
TERT mutations was similar in low-risk NMIBC (TaG1 and
TaG2; 33 of 45 [73%]), high-risk NMIBC (TaG3, Tis, T1G2,
T1G3; 34 of 46 [74%]), and in MIBC (10 of 19 [53%])
( p = 0.192) (Fig. 1C) and in newly diagnosed versus
recurrent tumors ( p = 0.716). TERT mutations were signif-
icantly more frequent among FGFR3 mutant tumors (43 of
49 vs 29 of 54; p = 0.0002).
We analyzed the twomost frequent TERTmutations in an
independent set of tumors from the Netherlands using a
specifically designed SNaPshot assay; mutations were
found to be mutually exclusive. A high mutation rate was
confirmed in both NMIBC (147 of 184 [80%]) and MIBC (136
of 173 [79%]) (Fig. 1C). To assess heterogeneity, we analyzed
TERT mutations using the SNaPshot assay in multiple
(median: 4; range: 2–5) regions of nine NMIBCs. We
observed general consistency among the regions, suggest-
ing a low level of intraindividual heterogeneity (Supple-
mental Table 2). These findings place TERTmutations as theTable 3 – Sensitivity and specificity of urine diagnostic assays
Variable The Netherlands,
no./total (%) n
Primary tumors, sensitivity FGFR3 17/42 (40)
TERT 21/37 (57)
TERT + FGFR3 20/28 (71)
Recurrent tumors, sensitivity FGFR3 15/68 (22)
TERT 18/63 (29)





TERT + FGFR3 131/183 (72)
FGFR3 = fibroblast growth factor receptor 3; FU = follow-up; TERT = telomerase remost common genetic alteration in UBC [6,7] and as an early
event in urothelial carcinogenesis.
TERT mutations have been proposed to generate novel
transcription factor binding sites leading to increased TERT
expression [12,13]. Mining the DNA-binding factor data-
base JASPAR, we performed a comparative analysis of the
wild-type and mutant sequences and found that the C228A
mutation newly reported in this paper was also associated
with an increased probability of binding to ELK1 (a member
of the ETS oncogene family) and v-ets avian erythroblastosis
virus E26 oncogene homolog 1 (ETS1), as the previously
reported mutations. The analysis revealed additional
transcription factors that could contribute to TERT over-
expression as well some that showed mutation selectivity,
such as v-rel avian reticuloendotheliosis viral oncogene
homolog (REL) for C242T/C243T or GATA bind protein 2
(GATA2) for C228A (Supplemental Table 3). To assess the
relationship between TERT mutations and mRNA levels, we
analyzed 60 primary UBC samples using RT-qPCR. TERT
mRNA levels were higher in TERT mutant tumors, but the
difference was not statistically significant (Wilcoxon test
p = 0.3). TERT mRNA levels were significantly higher in
high-risk NMIBC and in MIBC than in low-risk NMIBC
(Wilcoxon test p = 0.001) (Fig. 1D).
3.2. TERT mutations and patient outcome
The set of tumors from the Netherlands was used to assess
tumor prognostic value. Of 184 patients with NMIBC,
90 (49%) experienced progression to MIBC (Table 1). There
was no relationship between progression-free survival
and the presence of mutations (log-rank test p = 0.984)
(Supplemental Fig. 1). In the groupof173patientswithMIBC,
78 (45%) patients had local or distant progression and TERT
mutation status was not associated with progression-free
survival (log-rank test p = 0.160). Furthermore, 101 (58%)
patients died during follow-up, including 65 (37%) who died
of bladder cancer (Table 1). Overall- and cancer-specific
survival were not related to TERT mutations (log-rank tests
p = 0.987 and p = 0.834) (Supplemental Fig. 1). Among
patients with MIBC, 25 received adjuvant chemotherapy
with curative intent; TERTmutations were not predictive for






29/86 (34) 46/128 (36) –
52/81 (64) 73/118 (62) FGFR3 vs TERT, p < 0.0001
53/77 (69) 73/105 (70) TERT vs TERT + FGFR3, p = 0.23
9/56 (16) 24/124 (19) –
30/50 (60) 48/113 (42) FGFR3 vs TERT, p = 0.0001
31/50 (62) 52/103 (50) TERT vs TERT + FGFR3, p = 0.238
19/20 (95) 227/252 (90) –
11/18 (61) 160/218 (73) FGFR3 vs TERT, p < 0.0001
11/18 (61) 142/201 (71) TERT vs TERT + FGFR3, p = 0.529
verse transcriptase.
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Patients with NMIBC require continued follow-up due to
frequent tumor recurrences. We assessed whether TERT
mutations can be detected in exfoliated tumor cells in voided
urine and compared the findings with FGFR3 mutations
(Table 3). Of 39 urine samples from patients with hematuria
and inwhomno bladder tumorwas visible at cystoscopy (17
of 39 [44%] female; median age: 54 yr), 4 were positive for
TERT mutations, resulting in a specificity of 90%. None of
these four patients developed a UBC or another tumor in the
subsequent >3.5 yr. In urine samples obtained before
resection of a primary bladder tumor, the sensitivity of
incident tumor detection was 36% (46 of 128) for FGFR3, 62%
(73 of 118) for TERT, and 70% (73 of 105) for TERT and FGFR3
combined (FGFR3 vs TERT, p < 0.0001). We then tested 395
urine samples prospectively collected from 194 patients
under surveillance after a primary NMIBC diagnosis.
Sensitivity of detection of relapsing (recurrence or progres-
sion) UBC developing after a primary NMIBC was 19% (24 of
124) for FGFR3, 42% (48 of 113) for TERT, and 50% (52 of 103)
for both combined (FGFR3 vs TERT, p = 0.0001). In the
recurrence-freeurine samples, a TERTmutationwasdetected
in 58 of 218 cases, corresponding to a specificity of 73%,
whereas thespecificity for FGFR3mutationwas90% (FGFR3vs
TERT, p < 0.0001).
4. Discussion
TERT promoter hotspot mutations constitute a new type of
somatic genetic alterations in cancer. A recent survey in a
wide range of tumors indicated a selective mutational
pattern associated with tumor histology and tissue of origin
[14]. It has been proposed that mutations occur more
commonly in tumors derived from tissues with low
proliferation rates [12–14]. Based on the analysis of 21
UBCs, a high mutation rate was proposed, but there was no
clinical or pathologic information on these patients.
In this paper, we provide definitive evidence on the
occurrence of TERT promoter mutations in UBC. First, we
show a highmutation rate (70%), whichwas replicated in an
independent series (79%) using different assays, thus
making TERT the most frequently mutated gene in UBC.
Second,we show a similarmutation frequency across stages
and grades, strongly suggesting that TERT mutations
participate in the two major genetic pathways involved
in UBC. Third, we show a distinct mutational spectrum in
comparisonwithmelanomawith a dominance of the C228T
mutation. Finally, we show a lack of association with
progression in NMIBC or with the development of local or
distant metastases in MIBC.
The high frequency of hotspot mutations renders TERT a
very attractive target for diagnosis of bladder tumors, both
primary and recurrent, using body fluids such as urine or
blood. We show that tumor cell detection in urine is
feasible, with a sensitivity of 62% at initial diagnosis and 42%
at recurrence. For urine diagnostics during surveillance, the
patients were not stratified for mutation status of the
primary tumor; we expect that when this is performed,sensitivity of detection of recurrent UBC will increase.
Accordingly, TERT mutation was assayed concomitantly in
tumor tissue and urine in 31 cases: TERTwas concordant in
26 cases (19 mutated, 7 wild type), one tumor harbored a
C242T mutation not assessable by the SNaPshot assay, and
four mutations were detected in urine but not in tumor
samples. We show that TERT mutation detection has a
higher sensitivity than FGFR3 mutation for tumor cell
detection in urine, and assays of both TERT and FGFR3
mutations might have improved sensitivity, though the
difference was not statistically significant in our study.
By contrast, TERT mutations may have a lower specificity
than FGFR3 mutations, as four mutations were detected in
39 urine samples from patients without cancer and in 58 of
218 of patients in clinical remission. In this group, we
cannot distinguish reduced specificity from higher lead-
time bias in detection of tumor relapse. Larger, well-
designed, prospective studies are required to establish the
clinical usefulness of mutation detection in urine. As
previous reports have proposed TERT expression or activity
assessment in urine as a tool to detect recurrence, it will be
of high interest to compare TERT mutation with them and
with other candidate biomarkers in future studies [17,18].
Several observations support thenotion thatTERT somatic
mutations are an early event in urothelial carcinogenesis,
including their occurrence in a small fraction of subjects
without UBC, their presence in tumors of both the papillary
and invasive pathways, and the low level of intraindividual
heterogeneity when multiple tumor regions were analyzed.
UBC cell lines are also very frequently mutated, and we
noticed that most of the mutant ones lacked the wild-type
allele. These observations also suggest thatmutant cellsmay
display a growth advantage over wild-type cells.
The mechanisms through which TERT promoter muta-
tions contribute to UBC and other tumors remain to be
determined. One possibility is that the acquisition of new,
putative transcription binding sites leads to altered
regulation of gene expression, as previously proposed,
and also suggested by our bioinformatics analysis using the
DNA-binding factor database JASPAR. However, we failed to
find a significant association between TERT mutation and
expression. This could be explained by alternative mecha-
nisms of TERT upregulation in wild-type tumors, also
leading to TERT overexpression, or by the participation of
TERT mutations in additional biologic processes.
Given its reverse transcriptase activity, telomerase is a
potential therapeutic target. Recent developments suggest
that azidothymidine (AZT), an inhibitor of HIV reverse
transcriptase, also inhibits telomerase. Hence, it is conceiv-
able that AZT or other telomerase inhibitors may suppress
the growth of UBC overexpressing the enzyme [19].
One of the limitations of our work is the retrospective
nature of the cohorts used for the outcome analysis, even
though our results do not make positive claims. Another is
the lack of comparison for urine-based diagnostic assays
between TERT mutation, cytology, and other biomarkers.
However, the high frequency of these mutations in urine
reported herein provides evidence for future prospective and
comparative studies. Overall, the novelty of TERTmutation in
E U RO P E AN URO LOGY 6 5 ( 2 0 1 4 ) 3 6 0 – 3 6 6366UBC is strengthened by the independent analysis that we
performed in two different centers.
5. Conclusions
Mutations in the promoter of the TERT gene are the most
frequent somatic mutations in tumors of the urinary
bladder. Mutations occur with similar frequency, regardless
of stage or grade, and are not associated with clinical
outcome. TERT mutation assays may be used for tumor cell
detection in urine and TERT may be a therapeutic target.
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